Chromotek and Cell Culture Service Enter into a Partnership to Market Chromobody® Cell Lines
Chromobodies are single domain antibodies that are genetically fused to fluorescent proteins to serve as functional nanoprobes in living cells. The Chromobody®technology allows for the first time to trace endogenous intracellular antigens and to visualize dynamic changes of these targets in living cells. Currently available cell lines allow the high content analysis of the full cell cycle and real time monitoring of apoptotic events. Small molecule libraries can be screened for desired or adverse effects on a cellular level in multiwell formats. "The combination of dynamic live cell analysis and high content read out closes a gap in drug discovery and I am delighted to facilitate the use of this novel technology for my customers", states Dr. Oliver Wehmeier, Managing Director and President of Cell Culture Service. "We are impressed with CCS' capabilities to manufacture any type of cell based reagent in any type of cell and assay format for Chromobody® customers" says Dr. Marion Jung, Managing Director of Chromotek.
Customers who have licensed a cell line from Chromotek can order these cells from CCS directly. Customers who would like to get access to Chromotek's technology for the first time can license the cell line or order assay-ready frozen instant cells via Chromotek or via CCS.
About CCS Cell Culture Service
For more than eleven years, CCS has been supporting research departments of pharmaceutical and biotechnology companies in their efforts to discover new drug entities by supplying them with custom made functionally validated cell based reagents.
CCS is one of the leading suppliers of recombinant cell lines, assay-ready frozen cells, qualified membranes, and proteins for high-throughput screening.
Major pharmaceutical companies all over Europe and the USA now rely on the custom products and services of CCS.
Über ChromoTek GmbH
Chromotek products set new benchmarks for cellular research. The company was established in 2008 as a spin-off from Munich's Ludwig Maximilian University and is located in Martinsried, Germany's leading biotech cluster. Chromotek develops and markets immunological and bioimaging reagents and cellular assays for biomedical research and drug discovery. These include the GFP-Trap® for the rapid pull-down of GFP fusion proteins, GFP and RFP boosters for intensifying the fluorescence signal of GFP or RFP fusion proteins, Chromobody® based live cell assays for screening and validation and a fluorescence based protein-protein interaction assay called Fluorescent-2-Hybrid (F2H). More than 1.900 customers from all over the world trust in Chromotek products.
Weitere Pressemitteilungen dieses Herausgebers
- 18.04.2013 - ChromoTek wins INDUSTRY PRIZE 2013 for its pioneering Chromobody® technology for the real time analysis of cellular molecules in live cells
- 18.04.2013 - ChromoTek gewinnt Industriepreis 2013 für wegweisendes Chromobody® Verfahren zur Echtzeit-Analyse zelleigener Moleküle in lebenden Zellen
- 04.04.2013 - Analysis of complex protein-protein-interactions made easy